Form 4: Xeris Biopharma Director Garheng Kong Boosts Stake with 50,000 RSU Grant

Xeris Biopharma Holdings, Inc. Director Garheng Kong was granted 50,000 shares of common stock through a restricted stock unit award, increasing his total beneficial ownership to 214,144 shares.

Summary

• Garheng Kong, a Director of Xeris Biopharma Holdings, Inc. (XERS), acquired 50,000 shares of common stock on June 4, 2025.
• The acquisition was made pursuant to a restricted stock unit (RSU) award under the Company's 2018 Stock Option and Incentive Plan, with a transaction price of $0 per share.
• Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
• These 50,000 shares are scheduled to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.
• Following this transaction, Mr. Kong's total beneficial ownership in Xeris Biopharma Holdings, Inc. stands at 214,144 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even as a compensation grant, generally indicates alignment of interests and can be viewed positively by investors as it increases insider stake in the company's performance.

Positives

• The acquisition of 50,000 shares by a director, even through an RSU grant, indicates continued alignment of management and board interests with shareholder value.
• Increased insider ownership can signal confidence in the company's future prospects.

Future Outlook

This Form 4 filing does not provide a general future outlook for the company, focusing solely on an insider's stock transaction.

Industry Context

This filing is an individual insider transaction report and does not provide broader industry context or trends for the biopharma sector.

Related Party Transactions

• The acquisition of 50,000 restricted stock units by Director Garheng Kong is a transaction with a related party, consistent with standard compensation practices under the Company's 2018 Stock Option and Incentive Plan.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a director can be seen as a positive signal, aligning the director's financial interests more closely with those of the shareholders.

Next Steps

• The 50,000 restricted stock units are expected to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Key Dates

Keywords

Xeris Biopharma Holdings, XERS, Garheng Kong, Director, Insider Trading, Restricted Stock Units, RSU, Stock Grant, Beneficial Ownership, SEC Form 4, Biopharma